Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone and Pain Following Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled to undergo unilateral total knee arthroplasty.~* American Society of Anesthesiology (ASA) Physical Class 1-3.~* BMI \<40 kg/m2~Exclusion Criteria:~* Revision surgery.~* Bilateral total knee arthroplasty.~* Unicompartmental knee arthroplasty.~* Patients with a contraindication to regional anesthesia. This includes abnormal clotting, skin infection in groin or near the back, the presence of neurological disorders or anatomical abnormalities of the vertebral column.~* Contraindications or known drug interactions with dexamethasone.~* Use of any of the following medications within the times specified before surgery:~  * Long-acting opioid medication within 3 days.~ * Any opioid medication within 24 hours.~* Body weight less than 50 kilograms (\~110 pounds).~* Planned administration of another investigational product or procedure during the subject's participation in this study.~* Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.~* Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.~* Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postoperative course.~* Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function (Ejection fraction under 35%), epilepsy, myasthenia gravis), severe renal impairment (creatinine \> 1.8), comorbid conditions associated with an immunocompromised status, such as blood dyscrasias, HIV/AIDS, or recent chemotherapy.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone 6mg (Type: ACTIVE_COMPARATOR): Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
- Dexamethasone 12mg (Type: ACTIVE_COMPARATOR): Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
- Dexamethasone 24mg (Type: ACTIVE_COMPARATOR): Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.

Based on this trial design, predict the completion outcome and termination type (if applicable).